Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like N*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165002030	ADZENYS XR-ODT 12.5MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165002530	ADZENYS XR-ODT 15.7MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165003030	ADZENYS XR-ODT 18.8MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165000530	ADZENYS XR-ODT 3.1MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165001030	ADZENYS XR-ODT 6.3MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165001530	ADZENYS XR-ODT 9.4MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165020030	COTEMPLA XR-ODT 17.3MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.81	489.27	01/25/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165030030	COTEMPLA XR-ODT 25.9MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.81	489.27	01/25/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165010030	COTEMPLA XR-ODT 8.6MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.81	489.27	01/25/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	03/31/2023	72252051002	1 VALTOCO CARTON with 1 10 mg/.1mL VIAL	Brand	FDA	01/01/2023	37.40	660.68	03/27/2029	Single Source Drug	None	1	Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or “list prices” are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential.	None	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	03/31/2023	72252050502	1 VALTOCO CARTON with 1 5 mg/.1mL VIAL	Brand	FDA	01/01/2023	37.40	660.68	03/27/2029	Single Source Drug	None	1	Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or “list prices” are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential.	None	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	03/31/2023	72252052004	1 VALTOCO CARTON with 2 10 mg/.1mL VIALS	Brand	FDA	01/01/2023	37.40	660.68	03/27/2029	Single Source Drug	None	1	Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or “list prices” are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential.	None	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	03/31/2023	72252051504	1 VALTOCO CARTON with 2 7.5 mg/.1mL VIALS	Brand	FDA	01/01/2023	37.40	660.68	03/27/2029	Single Source Drug	None	1	Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or “list prices” are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential.	None	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2023	70370204001	INGREZZA ORAL CAPSULE 40 MG, BOTTLE OF 30 CAPSULES	Brand	FDA	12/09/2023	212.00	7514.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2023	70370106001	INGREZZA ORAL CAPSULE 60 MG, BOTTLE OF 30 CAPSULES	Brand	FDA	12/09/2023	233.00	8255.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2023	70370108001	INGREZZA ORAL CAPSULE 80 MG, BOTTLE OF 30 CAPSULES	Brand	FDA	12/09/2023	233.00	8255.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2023	70370204806	INGREZZA ORAL CAPSULE INITIATION PACK 40 MG (7) AND 80 MG (21), BLISTER PACK OF 28 CAPSULES	Brand	FDA	12/09/2023	233.00	8255.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000204	Noden Pharma USA, Inc.	03/31/2023	70839015030	TEKTURNA 150MG TAB 30/EA	Brand	FDA	01/09/2023	24.00	290.64	08/19/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This report was generated in conjunction with the Registered Prescriber notification (which was distributed via email in the required time period). While conducting internal year-end audit, unclear if this report was filed with California, so re-submitting due to possible oversight of submission.
Rx0000204	Noden Pharma USA, Inc.	03/31/2023	70839030030	TEKTURNA 300MG TAB 30/EA	Brand	FDA	01/09/2023	30.28	366.67	08/19/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This report was generated in conjunction with the Registered Prescriber notification (which was distributed via email in the required time period). While conducting internal year-end audit, unclear if this report was filed with California, so re-submitting due to possible oversight of submission.
Rx0000073	Novartis	03/31/2023	00078063968	COSENTYX® 150mg/ml Sensoready pen 150mg Dose 1 Sensoready pen	Brand	FDA	01/04/2023	452.99	6924.26	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078063941	COSENTYX® 150mg/ml Sensoready pen 300mg Dose 2 Sensoready pens	Brand	FDA	01/04/2023	452.99	6924.26	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078063997	COSENTYX® 150mg/ml Syringe 150mg Dose 1 prefilled syringe	Brand	FDA	01/04/2023	452.99	6924.26	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078063998	COSENTYX® 150mg/ml Syringe 300mg Dose 2 prefilled syringes	Brand	FDA	01/04/2023	452.99	6924.26	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078105697	COSENTYX® 75mg/0.5mL singledose prefilled syringe	Brand	FDA	01/04/2023	226.49	3462.13	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078065967	ENTRESTO® tablets 24mg/26mg 180s	Brand	FDA	01/04/2023	95.43	2003.94	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078077767	ENTRESTO® tablets 49mg/51mg 180s	Brand	FDA	01/04/2023	95.43	2003.94	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078077720	ENTRESTO® tablets 49mg/51mg 60s	Brand	FDA	01/04/2023	31.81	667.97	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078069667	ENTRESTO® tablets 97mg/103mg 180s	Brand	FDA	01/04/2023	95.43	2003.94	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078069620	ENTRESTO® tablets 97mg/103mg 60s	Brand	FDA	01/04/2023	31.81	667.97	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078065920	ENTRESTO® tablets 24mg/26mg 60s	Brand	FDA	01/04/2023	31.81	667.97	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078060715	GILENYA® capsules 0.5mg 30s	Brand	FDA	01/04/2023	681.88	10422.99	09/30/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078074303	ILEVRO® 0.3% 3 mL	Brand	FDA	01/04/2023	32.62	362.09	03/31/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078100768	KESIMPTA® 20 mg/0.4 mL singleuse Sensoready® pen (injection)	Brand	FDA	01/04/2023	534.10	8164.09	12/30/2027	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078090961	KISQALI® FEMARA® COPACK, Kisqali 1 blister pack, containing 21 tablets (200mg per tablet) (200mg daily dose), Femara 2.5mg 28s	Brand	FDA	01/04/2023	485.19	6550.11	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078091661	KISQALI® FEMARA® COPACK, Kisqali 3 blister packs, containing 14 tablets (200mg per tablet) (400mg daily dose), Femara 2.5mg 28s	Brand	FDA	01/04/2023	970.39	13100.27	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078092361	KISQALI® FEMARA® COPACK, Kisqali 3 blister packs, containing 21 tablets (200mg per tablet) (600mg daily dose), Femara 2.5mg 28s	Brand	FDA	01/04/2023	1212.99	16375.34	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078086001	KISQALI® tablets 200mg (200mg daily dose) 1 blister pack x 21 tablets (21 tablets per carton)	Brand	FDA	01/04/2023	485.19	6550.11	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078086742	KISQALI® tablets 200mg (400mg daily dose) 3 blister packs x 14 tablets (42 tablets per carton)	Brand	FDA	01/04/2023	970.39	13100.27	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078087463	KISQALI® tablets 200mg (600mg daily dose) 3 blister packs x 21 tablets (63 tablets per carton)	Brand	FDA	01/04/2023	1212.99	16375.34	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078097950	MAYZENT® tablets .25mg 28s	Brand	FDA	01/04/2023	140.95	2154.58	11/30/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078098615	MAYZENT® tablets 2mg 30s	Brand	FDA	01/04/2023	604.09	9233.93	11/30/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078070184	PIQRAY® tablets 200mg 28s	Brand	FDA	01/04/2023	1684.98	20406.96	09/28/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078071502	PIQRAY® tablets 250mg 56s	Brand	FDA	01/04/2023	1684.98	20406.96	09/28/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078070802	PIQRAY® tablets 300mg 56s	Brand	FDA	01/04/2023	1684.98	20406.96	09/28/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078097261	PROMACTA powder for oral suspension 12.5mg 30s Kit	Brand	FDA	01/04/2023	554.02	6709.85	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078069761	PROMACTA® powder for oral suspension 25mg 30s Kit	Brand	FDA	01/04/2023	554.05	6710.21	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068415	PROMACTA® tablets 12.5mg 30s	Brand	FDA	01/04/2023	554.02	6709.85	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068515	PROMACTA® tablets 25mg 30s	Brand	FDA	01/04/2023	554.02	6709.85	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068655	PROMACTA® tablets 50mg 14s	Brand	FDA	01/04/2023	467.88	5666.59	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068615	PROMACTA® tablets 50mg 30s	Brand	FDA	01/04/2023	1002.61	12142.71	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068715	PROMACTA® tablets 75mg 30s	Brand	FDA	01/04/2023	1503.91	18214.07	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078069819	RYDAPT® capsules for oral use 25mg 112s	Brand	FDA	01/04/2023	1597.12	21561.17	12/02/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078069899	RYDAPT® capsules for oral use 25mg 56s	Brand	FDA	01/04/2023	798.56	10780.59	12/02/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078070956	TABRECTATM tablets 150mg 56s	Brand	FDA	01/04/2023	799.15	10788.55	07/22/2035	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078071656	TABRECTATM tablets 200mg 56s	Brand	FDA	01/04/2023	799.15	10788.55	07/22/2035	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078068266	TAFINLAR® capsules 50mg 120s	Brand	FDA	01/04/2023	775.27	10466.12	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068166	TAFINLAR® capsules 75mg 120s	Brand	FDA	01/04/2023	999.13	13488.21	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078059287	TASIGNA® 150mg 112 capsules (4 Blister Packs of 28 capsules)	Brand	FDA	01/04/2023	1532.23	18556.96	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078052687	TASIGNA® 200mg 112 capsules (4 Blister Packs of 28 capsules)	Brand	FDA	01/04/2023	1532.23	18556.96	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078095166	TASIGNA® 50 mg capsules 120s	Brand	FDA	01/04/2023	1641.66	19882.38	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078091112	XIIDRA® 5% 50 mg/mL 60count carton, 12 pouches of 5 singleuse containers (0.2mL each)	Brand	FDA	01/04/2023	50.70	684.45	12/18/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	05/09/2019	Takeda Pharmaceutical Company	3400000000	None	Novartis paid $3.4 billion upfront, plus potential milestone payments of up to $1.9 billion.	553.54	507.00	2016	426.73	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Product was acquired from Takeda. Acquisition of product was finalized 10/1/2019.
Rx0000073	Novartis	03/31/2023	00078069484	ZYKADIA® 150mg 84s tablets	Brand	FDA	01/04/2023	1096.91	12176.79	02/02/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000017	Noven Therapeutics, LLC	03/31/2023	68968555203	Daytrana Transdermal Patch 10 MG/9HR - 30 each	Brand	FDA	01/01/2023	22.04	463.01	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2023	68968555303	Daytrana Transdermal Patch 15 MG/9HR - 30 each	Brand	FDA	01/01/2023	22.04	463.01	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2023	68968555403	Daytrana Transdermal Patch 20 MG/9HR - 30 each	Brand	FDA	01/01/2023	22.04	463.01	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2023	68968555503	Daytrana Transdermal Patch 30 MG/9HR - 30 each	Brand	FDA	01/01/2023	22.04	463.01	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None